Barry Keenan Appointed Vice President of Engineering of BioSig Technologies

Barry Keenan has been appointed vice president of engineering of BioSig Technologies.

BioSig is a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace

Dr. Keenan brings to the Company over 20 years of experience in R&D, product development and commercialization and deep industry expertise in a range of sectors, including neuromodulation, deep brain stimulation, sensing, imaging and cardiac pacing. Biomedical engineer by training, Dr. Keenan spent over 9 years at Medtronic Diabetes, where he was responsible for all algorithm development, and successfully developed the algorithms for the MiniMedTM ParadigmTM VeoTM, first semi-closed loop system, and iProTM2  Professional Continuous Glucose Monitoring (CGM), glucose monitoring algorithm. One of the highlights of Dr. Keenan’s career was development and successful clinical evaluation of the MiniMedTM 670G, the world’s first artificial pancreas. This invention became one of the top revenue generating products for Medtronic and the research was featured in Time magazine’s 25 Best Inventions of 2013 and 2016 and named as one of the Best Medical Technologies of 2016.

Since 2014, Dr. Keenan has been actively involved with the Alfred Mann Foundation for Scientific Research as CTO and Vice President of Research & Development, and later as a Board Member of the Alfred Mann Institute for Biomedical Engineering. During Dr. Keenan’s engagement with the Foundation he managed an R&D department of over 40 scientists and engineers consisting of software, firmware, electrical, mechanical and ASIC groups developing innovative medical devices, implanted neuromodulation and sensing systems.

Dr. Keenan is a winner of several awards, is a Medtronic Technical Fellow, and is being inducted into this year’s College of Fellows of the American Institute for Medical and Biological Engineering (AMIBE). His team at Medtronic won Technical Contributors of the Year for their work in the Artificial Pancreas, which also achieved ‘Best of What’s New’ in the health category by Popular Science. Dr. Keenan is an inventor of 39 patents and authored over 30 scientific manuscripts and book chapters.

“Barry’s second-to-none academic training and industry expertise are very hard to come by, and we are particularly impressed with his achievements in neuromodulation,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies. “As we accelerate our research activities, we need strong engineering leadership and commercial expertise to grow our product development. We are confident that Barry will become an invaluable part of our team.”

“Having followed BioSig’s development over the years, I am excited about its future as a technology company with cutting-edge signal processing capabilities. I look forward to contributing my knowledge and exploring opportunities for wider applications of BioSig’s core technology,” commented Dr. Keenan.

The Company previously appointed Sherpa Technology Group to architect IP strategy and announced a new advanced research agreement with Mayo Clinic in November 2018.

On February 20, 2019 the Company announced that it successfully conducted first patient cases using PURE EPTM System, its FDA approved proprietary signal acquisition and processing technology. Early results of the studies suggested improved cardiac signal detection and fidelity.